S2E7 - Infliximab, Antipsychotic Duration, and Dimensional Diagnosis

The Psych Review

The seventh episode of season two of The Psych Review finds Dave looking internationally (again) at the use of infliximab in the treatment of bipolar depression, see's Shakira explore how we should talk about duration of antipsychotic treatment with patients with schizophrenia, and allows Mazz to have a rant about whether personality disorder diagnosis should be typological or dimensional.
The articles covered in this month's episode are:
- Dave: McIntyre, R. S., Subramaniapillai, M., Lee, Y., Pan, Z., Carmona, N. E., Shekotikhina, M., ... & Miller, S. (2019). Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial. JAMA psychiatry.
- Shakira: Bendall, S. (2019). Costs versus benefits and impact on life goals should be part of communication around anti-psychotic treatment duration in schizophrenia. Australian & New Zealand Journal of Psychiatry, 53(8), 811–812. https://doi.org/10.1177/0004867419860905
- Mazz: Irwin, L. and Mahli, S. G. (2019). Borderline personality disorder and ICD-11: A chance for change. Australian and New Zealand Journal of Psychiatry, 53(7) pages 698-700.
The Psych Review was brought to you by Call to Mind, a new telepsychiatry service that you can learn more about at www.calltomind.com.au. The original music in our podcast was provided by the very talented John Badgery, and our logo was designed by the creative genius of Naz.